Stay updated with breaking news from Humanized Mouse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Genprex, Inc. (GNPX) reported that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing the non-viral Oncoprex Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer in a humanized mouse model.
The humanized mouse and rat model market boasts a total revenue value of $349 million by 2028.
Dublin, May 22, 2023 (GLOBE NEWSWIRE) -- The "Global Humanized Mouse and Rat Model Market by Type (Genetic, Cell-based (CD34, PBMC, BLT)), Application...
/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
/PRNewswire/ -- In many ways, our intestines serve as the front gate between our bodies and the world around us. They help digest our food and absorb our...